Atlas Trials

Humanized Monoclonal Antibody 3F8 (Hu3F8) With Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in the Treatment of Recurrent Osteosarcoma

Clinical trial NCT02502786 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT02502786
Sponsor
Memorial Sloan Kettering Cancer Center
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Recurrent Osteosarcoma
Start date
2015-07-01
Primary completion
2027-07-01
Enrollment
46

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.